Efficacy and safety of a novel DPP-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus - The results of clinical trials in Japan

Japanese Pharmacology and Therapeutics

Volumn 41, Issue 8, 2013, Pages 803-815

  Kadowaki, Takashi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Saxagliptin; Selective DPP 4 inhibitor; Type 2 diabetes mellitus

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; METFORMIN; ORAL ANTIDIABETIC AGENT; SAXAGLIPTIN; SULFONYLUREA; THIAZOLIDINE DERIVATIVE;

CLINICAL TRIAL (TOPIC); DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; JAPAN; LONG TERM CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; REVIEW; WEIGHT GAIN;

EID: 84884241834     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Kadowaki T, Miyake Y, Hagura R, Akanuma Y, Kajinuma H, Kuzuya N, et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia 1984; 26 : 44-9. (Pubitemid 14182349)
2. Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 2004; 66S : S37-S43. (Pubitemid 39572582)
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329 : 977-86.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352 : 837-53.
5. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28 : 103-17.
6. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355 : 2427-43.
7. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide I. Proc Natl Acad Sci USA 1992; 89 : 8641-5.
8. Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 1993; 133 : 2861-70. (Pubitemid 24000747)
9. Preitner F, Ibberson M, Franklin I, Binnert C, Pende M, Gjinovci A, et al. Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest 2004; 113 : 635-45. (Pubitemid 38542513)
10. Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of type 2 diabetes mellitus. Diabetologia 2001; 44 : 929-45. (Pubitemid 32778125)
11. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86 : 3717-23. (Pubitemid 32755966)
12. Nauck MA, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29 : 46-52. (Pubitemid 16162741)
13. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal : Effects of exogenous glucagon-like peptide-1 (GLP-1)- (7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996; 81 : 327-32.
14. Drucker DJ, Nauck MA. The incretin system : glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368 : 1696-705. (Pubitemid 46048557)
15. Frederich R, Alexander JH, Fiedorek FT, Donovan M, Berglind N, Harris S, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010; 122 : 16-27.
16. Kirby M, Yu DM, O'Connor S, Gorrell MD. Inhibitor selectivity in the clinical application of dipeptidyl peptidases inhibition. Clin Sci (Lond) 2009; 118 : 31-41.
17. Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin 2012; 28 : 513-23.
18. Boulton DW, Li L, Frevert EU, Tang A, Castaneda L, Vachharajani NN, et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet 2011; 50 : 253-65.
19. Nowicki M, Rychlik I, Haller H, Warren M, Suchower L, Gause-Nilsson I, et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment : a randomised controlled 52-week efficacy and safety study. Int J Clin Pract 2011; 65 : 1230-9.
20. Scirica BM, Bhatt DL, Braunwald E, Steg G, Davidson J, Hirshberg B, et al. The design and rationale of saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus : thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J 2011; 162 : 818-25.